Company profile VIRX
There is not enough data for Viracta Therapeutics biotechnology to provide analysis
There is not enough data for Viracta Therapeutics biotechnology to provide correlation calculation
There is not enough data for Viracta Therapeutics biotechnology to provide analysis
There is not enough data for nanatinostat to provide analysis
There is not enough data for nanatinostat to provide correlation calculation
There is not enough data for nanatinostat to provide analysis
After 39 days of this quarter the interest is at 224.0. Based on that we can calculate that during remaining 52 days it will total up to 523.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 368 | 659 79.1% QoQ | 727 10.3% QoQ | 685 -5.8% QoQ |
| 2020 | 614 66.8% YoY -10.4% QoQ | 481 -27.0% YoY -21.7% QoQ | 727 0.0% YoY 51.1% QoQ | 639 -6.7% YoY -12.1% QoQ |
| 2021 | 528 -14.0% YoY -17.4% QoQ | 627 30.4% YoY 18.8% QoQ | 595 -18.2% YoY -5.1% QoQ | 794 24.3% YoY 33.4% QoQ |
| 2022 | 824 56.1% YoY 3.8% QoQ | 600 -4.3% YoY -27.2% QoQ | 593 -0.3% YoY -1.2% QoQ | 694 -12.6% YoY 17.0% QoQ |
| 2023 | 701 -14.9% YoY 1.0% QoQ | 890 48.3% YoY 27.0% QoQ | 724 22.1% YoY -18.7% QoQ | 654 -5.8% YoY -9.7% QoQ |
| 2024 | 224 -68.0% YoY -65.7% QoQ | - | - | - |
The average 5 years interest of valganciclovir was 51.14 per week. The last year interest of valganciclovir compared to the last 5 years has changed by 8.19%. The interest for valganciclovir is seasonal. The last year interest is comparable to 5 years ago. It has changed only by 7.83%.
There is not enough data for Nana-val clinical trials to provide analysis
There is not enough data for Nana-val clinical trials to provide correlation calculation
There is not enough data for Nana-val clinical trials to provide analysis
There is not enough data for EBV+ lymphoma treatment to provide analysis
There is not enough data for EBV+ lymphoma treatment to provide correlation calculation
There is not enough data for EBV+ lymphoma treatment to provide analysis
There is not enough data for nasopharyngeal carcinoma treatment to provide analysis
There is not enough data for nasopharyngeal carcinoma treatment to provide correlation calculation
There is not enough data for nasopharyngeal carcinoma treatment to provide analysis
There is not enough data for virus-associated cancers to provide analysis
There is not enough data for virus-associated cancers to provide correlation calculation
There is not enough data for virus-associated cancers to provide analysis
After 39 days of this quarter the interest is at 170.0. Based on that we can calculate that during remaining 52 days it will total up to 397.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 174 | 425 144.3% QoQ | 298 -29.9% QoQ | 319 7.0% QoQ |
| 2020 | 322 85.1% YoY 0.9% QoQ | 374 -12.0% YoY 16.1% QoQ | 318 6.7% YoY -15.0% QoQ | 320 0.3% YoY 0.6% QoQ |
| 2021 | 392 21.7% YoY 22.5% QoQ | 342 -8.6% YoY -12.8% QoQ | 332 4.4% YoY -2.9% QoQ | 353 10.3% YoY 6.3% QoQ |
| 2022 | 491 25.3% YoY 39.1% QoQ | 615 79.8% YoY 25.3% QoQ | 419 26.2% YoY -31.9% QoQ | 488 38.2% YoY 16.5% QoQ |
| 2023 | 499 1.6% YoY 2.3% QoQ | 620 0.8% YoY 24.2% QoQ | 607 44.9% YoY -2.1% QoQ | 576 18.0% YoY -5.1% QoQ |
| 2024 | 170 -65.9% YoY -70.5% QoQ | - | - | - |
The average 5 years interest of precision oncology was 32.39 per week. The last year interest of precision oncology compared to the last 5 years has changed by 35.38%. The interest for precision oncology is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 74.56%.
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. vecabrutinib expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 121 inf% QoQ | 55 -54.5% QoQ | 90 63.6% QoQ |
| 2020 | 91 inf% YoY 1.1% QoQ | 66 -45.5% YoY -27.5% QoQ | 0 -100.0% YoY -100.0% QoQ | 74 -17.8% YoY inf% QoQ |
| 2021 | 24 -73.6% YoY -67.6% QoQ | 141 113.6% YoY 487.5% QoQ | 136 inf% YoY -3.5% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2022 | 135 462.5% YoY inf% QoQ | 98 -30.5% YoY -27.4% QoQ | 88 -35.3% YoY -10.2% QoQ | 61 inf% YoY -30.7% QoQ |
| 2023 | 115 -14.8% YoY 88.5% QoQ | 122 24.5% YoY 6.1% QoQ | 20 -77.3% YoY -83.6% QoQ | 138 126.2% YoY 590.0% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of vecabrutinib was 6.03 per week. The last year interest of vecabrutinib compared to the last 5 years has changed by 13.93%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 4.09%.
There is not enough data for VRx-510 PDK-1 inhibitor. to provide analysis
There is not enough data for VRx-510 PDK-1 inhibitor. to provide correlation calculation
There is not enough data for VRx-510 PDK-1 inhibitor. to provide analysis